Tag: Bharat Biotech

The representatives from the Central Asian nation of 41 million people took a tour of the world-class Bio-Safety Level 3 manufacturing facility....................

Dr Krishna M. Ella, Mrs.Suchitra Ella and Dr Balram Bhargav are being honored in BioAsia 2021...............

Recently, Bharat Biotech has applied for regulatory approval to conduct clinical trials in Bangladesh and has applied for EUA in the Philippines.....................

Ocugen to receive an initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US. The vaccine is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients...........

Experts believe that the largest ever allocation in the history of the vaccine industry would catalyze research and development efforts in the area....................

Bharat Biotech to produce antigen for world’s first vaccine against Plasmodium falciparum malaria following technology transfer, to help ensure long-term sustainable supply. Transfer builds on GSK commitments to donate up to 10 million vaccine doses.......................

After adequate examination, Central Drugs Standard Control Organisation decided to accept the recommendations of the Expert Committee, and accordingly, vaccines of Serum and Bharat Biotech are being approved for restricted use in an emergency situation

On 28th November, Prime Minister of India, Narendra Modi undertook a three-city tour to the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad, and Serum Institute of India in Pune......................

Human trials of India’s first indigenous experimental vaccine against COVID-19, COVAXIN, developed by Bharat Biotech is set to begin across India in July........................

The Coalition for Epidemic Preparedness Innovations (CEPI) will provide consortium comprising Bharat Biotech (BBIL) and the International Vaccine Institute (IVI) with up to US$14.1 million for vaccine manufacturing and clinical development of a two-dose live-inactivated vaccine (BBV87) against Chikungunya..............